|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multidisciplinary approach for patients with esophageal cancer显示文摘Patients with esophageal cancer have a poor prognosis because they often have no symptoms until their disease is advanced. There are no screening recommendations for patients unless they have Barrett's esophagitis or a significant family history of this disease. Often, esophageal cancer is not diagnosed until patients present with dysphagia, odynophagia, anemia or weight loss. When symptoms occur, the stage is often stage Ⅲ or greater. Treatment of patients with very early stage disease is fairly straight forward using only local treatment with surgical resection or endoscopic mucosal resection. The treatment of patients who have locally advanced esophageal cancer is more complex and controversial. Despite multiple trials, treatment recommendations are still unclear due to conflicting data. Sadly, much of our data is difficult to interpret due to many of the trials done have included very heterogeneous groups of patients both histologically as well as anatomically. Additionally, studies have been underpowered or stopped early due to poor accrual. In the United States, concurrent chemoradiotherapy prior to surgical resection has been accepted by many as standard of care in the locally advanced patient. Patients who have metastatic disease are treated palliatively. The aim of this article is to describe the multidisciplinary approach used by an established team at a single high volume center for esophageal cancer, and to review the literature which guides our treatment recommendations. | Victoria M Villaflor Marco E Allaix Bruce Minsky Fernando A Herbella Marco G Patti | 2012 | World Journal of Gastroenterology2012，18，46： | 9 |
| 2 | Impact of minimally invasive surgery on the treatment of benign esophageal disorders显示文摘Thanks to the development of minimally invasive surgery, the last 20 years have witnessed a change in the treatment algorithm of benign esophageal disorders. Today a laparoscopic operation is the treatment of choice for esophageal achalasia and for most patients with gastroesophageal reflux disease. Because the pathogenesis of achalasia is unknown, treatment is palliative and aims to improve esophageal emptying by decreasing the functional obstruction at the level of the gastro-esophageal junction. The refinement of minimally invasive techniques accompanied by large, multiple randomized control trials with long-term outcome has allowed the laparoscopic Heller myotomy and partial fundoplication to become the treatment of choice for achalasia compared to endoscopic procedures, including endoscopic botulinum toxin injection and pneumatic dilatation. Patients with suspected gastroesophageal reflux need to undergo a thorough preoperative workup. After establishing diagnosis, treatment for gastroesophageal reflux should be individualized to patient characteristics and a decision about an operation made jointly between surgeon and patient. The indications for surgery have changed in the last twenty years. In the past, surgery was often considered for patients who did not respond well to acid reducing medications. Today, the best candidate for surgery is the patient who has excellent control of symptoms with proton pump inhibitors. The minimally invasive approach to antireflux surgery has allowed surgeons to control reflux in a safe manner, with excellent long term outcomes. Like achalasia and gastroesophageal reflux, the treatment of patients with paraesophageal hernias has also seen a major evolution. The laparoscopic approach has been shown to be safe, and durable, with good relief of symptoms over the long-term. The most significant controversy with laparoscopic paraesophageal hernia repair is the optimal crural repair. This manuscript reviews the evolution of these techniques. | Brian Bello Fernando A Herbella Marco E Allaix Marco G Patti | 2012 | World Journal of Gastroenterology2012，18，46： | 6 |
| 3 | Gastroesophageal reflux disease and morbid obesity: To sleeve or not to sleeve?显示文摘Laparoscopic sleeve gastrectomy(LSG) has reached wide popularity during the last 15 years, due to the limited morbidity and mortality rates, and the very good weight loss results and effects on comorbid conditions. However, there are concerns regarding the effects of LSG on gastroesophageal reflux disease(GERD). The interpretation of the current evidence is challenged by the fact that the LSG technique is not standardized, and most studies investigate the presence of GERD by assessing symptoms and the use of acid reducing medications only. A few studies objectively investigated gastroesophageal function and the reflux profile by esophageal manometry and 24-h p H monitoring, reporting postoperative normalization of esophageal acid exposure in up to 85% of patients with preoperative GERD, and occurrence of de novo GERD in about 5% of cases. There is increasing evidence showing the key role of the surgical technique on the incidence of postoperative GERD. Main technical issues are a relative narrowing of the mid portion of the gastric sleeve, a redundant upper part of the sleeve(both depending on the angle under which the sleeve is stapled), and the presence of a hiatal hernia. Concomitant hiatal hernia repair is recommended. To date, either medical therapy with proton pump inhibitors or conversion of LSG to laparoscopic Rouxen-Y gastric bypass are the available options for the management of GERD after LSG. Recently, new minimally invasive approaches have been proposed in patients with GERD and hypotensive LES: the LINX? Reflux Management System procedure and the Stretta? procedure. Large studies are needed to assess the safety and long-term efficacy of these new approaches. In conclusion, the recent publication of p H monitoring data and the new insights in the association between sleeve morphology and GERD control have led to a wider acceptance of LSG as bariatric procedure also in obese patients with GERD, as recently stated in the 5^(th) International Consensus Conference on sleeve gastrectomy. | Fabrizio Rebecchi Marco E Allaix Marco G Patti Francisco Schlottmann Mario Morino | 2017 | World Journal of Gastroenterology2017，23，13： | 4 |
| 4 | Short-term,high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN trial显示文摘 | Patti G Ricottini E Nusca A | 2011 | Am J Cardiol2011，108，1： | 1 |
| 5 | Bank Competition and Firm Creation 显示文摘 | Bonaccorsi Di Patti E Dell Aricca G | 2004 | Journal of Money Credit and Banking2004，36，： | 1 |
| 6 | Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percu- taneous coronary intervention (from the ARMYDA- CIN trial 显示文摘 | Patti G Ricottini E Nusca A | 2011 | Am J Cardiol2011，108，： | 1 |
| 7 | Serological evidence for Borna disease virus infection in children, cats and horses in Sicily (Italy) 显示文摘 | Patti AM Vulcano A Candelori E | 2008 | APMIS Suppl2008，，124： | 1 |
| 8 | Short-term, high-dose Ator- vastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN triM显示文摘 | Patti G Ricottini E Nusca A | 2011 | Am J Cardiol2011，108，1： | 1 |
| 9 | Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes:potential role of PGC1 and NRFl显示文摘 | PATTI M E BUTTE A J CRUNKHORN S | 2003 | Proc Natl Acad Sci USA2003，100，： | 1 |
| 10 | Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene显示文摘 | Araki E Lipes MA Patti ME | 1994 | Nature1994，372，6502： | 1 |
| 11 | Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1gene显示文摘 | Araki E Lipes MA Patti ME | 1994 | Nature1994，372，652： | 1 |
| 12 | Capital struc- ture and firm performance:A new approach to testing agen- cy theory and an application to the banking industry 显示文摘 | BERGER A N BONACCORSI DI PATTI E | 2006 | Journal of Banking & Finance2006，30，4： | 1 |
| 13 | Mate real blood lead effects on infant intelligence at age 显示文摘 | Emory E Ansari Z Patti R | 2003 | Obstet Gynecol2003，188，4： | 1 |
| 14 | Short-term, high-dose atorvastatin pretreatment to prevent contrast-inducednephropathy in patients with acute coronary syndromes un-dergoing percutaneous coronary intervention ( from the AR-MYDA-CIN trial 显示文摘 | Patti G Ricottini E Nusca A | 2011 | Am J Cardiol2011，108，1： | 1 |
| 15 | Metabolic effects of vanadyl sulfate in humans with non--insulin- dependent diabetes mellitus: In vivo and in vitro studies 显示文摘 | Goldfine A Patti M E Zuberi L | 2000 | Metabolism2000，49，3： | 1 |
| 16 | Short-term, high-dose? Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acutecoronary syndromes undergoing pereutaneous coronary intervention (from the ARMYDA-CIN trial显示文摘 | Patti G Ricottini E Nusca AA | 2011 | Am J Cardiol2011，108，1： | 1 |
| 17 | Viral load of human papillomavirus and risk of CIN3 or cervical cancer显示文摘 | Attila T Lorincz Philip E Castle Mark E Sherman David R Scott Andrew G Glass Sholom Wacholder Brenda B Rush Patti E Gravitt John E Schussler Mark Schiffman | 2002 | The Lancet . 2002 (9328)2002，，9328： | 1 |
| 18 | Financial sector liberalization, bank privatization, and efficiency: Evidence from Pakistan 显示文摘 | Patti E Hardy D | 2005 | Journal of Banking & Finance2005，29，： | 1 |
| 19 | Activation of the Hexosamine Pathway by Glucosamine in Vivo Induces Insulin Resistance of Early Postreceptor Insulin Signaling Events in Skeletal Muscle 显示文摘 | Patti M E Virkamaki A Landaker E J | 1999 | Diabetes1999，48，8： | 1 |
| 20 | Measurement of the sensible eddy heat flux based on spatial averaging of continuous ground-based observations显示文摘 | Mauder M Desjardins R L Patty E | 2008 | Boundary-Layer Meteorology2008，128，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员